



Pfizer Canada Inc.

March 28, 2007

Mr. Eddie Vos
127 Courser
Sutton, QC
J0E 2K0

Dear Mr. Vos,


Your request was forwarded to us by Dr. Connie Newman, lead author of the *Comparative Safety of Atorvastatin 80 mg versus 10 mg Derived from Analysis of 49 Completed Trials in 14,236 patients* published in the *American Journal of Cardiology* in 2006.

We understand that you have requested specific data on the actual mortality numbers in each of the groups in the pooled analysis comparing the safety of atorvastatin 80 mg to atorvastatin 10 mg and placebo. Please be advised that the data that you are requesting is unpublished data and that Pfizer's corporate policy is to disclose unpublished data to healthcare professionals only when required to make an appropriate clinical decision related to a specific patient. Therefore, we refer you to the publication which indicates that the incidence of death was low, less than or equal to 0.4 per cent per group.¹ Please note that no further information than that presented in the article published in the *American Journal of Cardiology* will be provided.

We realize that this decision may cause you some inconvenience. We trust that you will understand our decision.

Sincerely,

Stéphanie Vézina, B.Pharm.
Senior Medical Information Specialist
Pfizer, Canada Inc.



Christian Marcoux
Manager, Corporate Communications
Pfizer Canada

References

1. Newman C et al. Comparative Safety of Atorvastatin 80 mg versus 10 mg Derived from Analysis of 49 Completed Trials in 14,236 Patients. *Am J Cardiol* 2006; 97(1):61-7.